Surgery and radiofrequency ablation showed similar 5-year survival rates for small liver tumors. Both treatments had nearly identical 5-year recurrence-free survival outcomes. Patient and tumor ...

Background and Aim Surgery is the standard treatment option for hepatocellular carcinoma (HCC) meeting the Milan criteria, defined as single HCC ≤ 5 cm in maximum diameter or up to three nodules ≤ 3 ...

This study calculated survival rates for 2 treatment approaches to patients with early stage recurrent hepatocellular carcinoma (HCC). At 5 years, patients who underwent a repeat hepatectomy versus ...

Adults with papillary thyroid microcarcinoma may spend less time and money without sacrificing treatment benefits if they have radiofrequency ablation rather than thyroid surgery, according to ...

A recent report suggesting significant cost-effectiveness advantage for renal radiofrequency ablation (RFA) over partial nephrectomy makes assumptions about rates of local cancer recurrence, estimates ...

Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. This is an ASCO Meeting Abstract ...

Early tumor formation in Barrett's esophagus can be effectively and safely treated with radiofrequency ablation in combination with prior endoscopic removal of visible lesions, according to a new ...

Radiofrequency ablation (RFA) is a procedure aiming to shrink the sizes of nodules and tumors or treat pain. RFA is not a cure-all solution, however. Back pain may not go away after RFA or may come ...

As radiofrequency ablation (RFA) in the treatment of benign thyroid nodules gains favor as a noninvasive alternative to surgery in the United States, clinicians are increasingly reporting their ...

Please provide your email address to receive an email when new articles are posted on . Endoscopic mucosal resection followed by radiofrequency ablation had a better safety profile for managing ...

Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer. Background: Which is superior to treat hepatocellular carcinoma (HCC), surgery or percutaneous ablation?